Filana Therapeutics, Inc. Common Stock (FLNA) Stock Price

FLNAStock
$0.93
Market Cap$44.88M
P/E
PEG Ratio1.62
Div yield
Beta1.38

FLNA Share Price Chart

Favorite Metrics

Price vs S&P 500 (4W)-11.35%
PEG Ratio1.62
VGM Score56.01

FLNA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.23-$0.18+20.00%(+$0.05)
Q1 2026-$0.23-$0.21+8.70%(+$0.02)
Q4 2025-$0.30-$0.26+13.33%(+$0.04)
Q3 2025-$0.27-$0.22+18.52%(+$0.05)
Q2 2025-$0.92

FLNA Analyst Recommendations

Dec 2025
Jan 2026
Feb 2026
Mar 2026
4.00
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
FLNAFilana Therapeutics, Inc. Common Stock
AD$0.93
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Filana Therapeutics, Inc. Common Stock

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.